Login
Register
Submit a Paper
Propose a Special lssue
Open Access
ARTICLE
Pharmacology of phosphodiesterase 5 inhibitors
McGill University Health Centre, Montreal, Quebec, Canada
Address correspondence to Dr. Serge Carrier, CUSM-Royal
Victoria Hospital, 687 ave des Pins Ouest, Montreal, QC
H3A 1A1 Canada
Canadian Journal of Urology 2003, 10(Suppl.1), 12-16.
Download PDFAbstract
The phosphodiesterase enzymes, of at least 11 types, are ubiquitous throughout the body, and perform a variety of functions. Phosphodiesterase type 5 (PDE5) is the predominant enzyme in the corpus cavernosum, and plays a crucial role in penile erection. Inhibitors of PDE5 are the most effective oral agents in the treatment of erectile dysfunction. Sildenafil, tadalafil, and vardenafil are all potent inhibitors of PDE5 and show the same mechanism of action, although they have some pharmacological differences that may translate into varying clinical effects.Keywords
phosphodiesterase 5 inhibitors, tadalafil
Cite This Article
APA Style
Carrier, S. (2003). Pharmacology of phosphodiesterase 5 inhibitors. Canadian Journal of Urology, 10(Suppl.1), 12–16.
Vancouver Style
Carrier S. Pharmacology of phosphodiesterase 5 inhibitors. Can J Urology. 2003;10(Suppl.1):12–16.
IEEE Style
S. Carrier, “Pharmacology of phosphodiesterase 5 inhibitors,” Can. J. Urology, vol. 10, no. Suppl.1, pp. 12–16, 2003.
Copyright © 2003 The Author(s). Published by Tech Science Press.This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Downloads
Citation Tools
